Is TScan Therapeutics (TCRX) stock Halal?

TScan Therapeutics operates as a clinical-stage biotechnology company focused on the development of T-cell receptor-engineered T cell (TCR-T) therapies for the treatment of cancer. The company's primary function is to harness the power of the immune system to battle various forms of cancer through innovative TCR-T technology. By engineering T cells to recognize and attack tumor cells, TScan aims to provide novel treatment options for patients with unmet medical needs. Before any of that matters to a Muslim investor, one question comes first: is TScan Therapeutics stock Halal?

Is TScan Therapeutics Shariah compliant?

No. In the October 2026 screening TScan Therapeutics (TCRX) does not pass AAOIFI screening: it fails the non-permissible income, interest-bearing investments and interest-bearing debt screens. The Shariah case on a technology company like TScan Therapeutics is rarely about the product. What AAOIFI Shariah Standard No. 21 examines is the money around the product: cash parked in instruments that earn Riba, borrowing measured against a market capitalisation that moves daily, and any incidental income from sources Islam prohibits, which must stay below 5% of revenue.

Does TScan Therapeutics pass the business activity test?

The activity screen is only part of the picture this month: TScan Therapeutics currently fails the non-permissible income, interest-bearing investments and interest-bearing debt screens, so the overall verdict is not compliant regardless of the business itself. The watch item for technology names is incidental: cash returns and platform content can carry impermissible elements, which AAOIFI tolerates only below the thresholds.

Is TScan Therapeutics' income Halal?

No. TScan Therapeutics' income from impermissible sources currently exceeds AAOIFI's 5% revenue ceiling, which makes the stock non-compliant on this screen regardless of the others. The screen is reassessed monthly, so the status can change when new financial statements arrive.

Does TScan Therapeutics meet AAOIFI's debt and investment ratio requirements?

No. Both ratios currently breach the 30% caps, measured against a market capitalisation of $20.6M (market data as of 1 October 2026): interest bearing investments and interest bearing debt each exceed the limit AAOIFI permits for a Halal investment. The ratios move with the share price as well as the balance sheet, and our Shariah Supervisory Board has TCRX re-screened every month.

Why do other halal screeners show a different verdict for TScan Therapeutics?

Screeners can disagree without either being wrong. AAOIFI Shariah Standard No. 21, which Tabadulat applies, measures interest bearing debt and investments against market capitalisation with a 30% ceiling. MSCI and FTSE measure them against total assets with a 33% ceiling, and S&P and Dow Jones Islamic use a multi year average of market capitalisation. Data dates differ too, because each provider reads filings and prices on its own schedule. The same company can therefore pass one standard and fail another in the same month. Tabadulat publishes one answer, the AAOIFI result as of October 2026, and re-screens it every month.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the screening method? Read Why a Halal Stock Screener Matters for Halal Investing